AB 154

Drug Profile

AB 154

Alternative Names: AB154

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Abmuno Therapeutics
  • Developer Arcus Biosciences
  • Class Antibodies; Antineoplastics
  • Mechanism of Action TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Apr 2017 Preclinical trials in Cancer in USA (unspecified route) (Arcus Biosciences pipeline, April 2017)
  • 18 Apr 2017 Pharmacodynamics data from preclinical trials in Cancer released by Arcus Biosciences
  • 18 Apr 2017 Arcus Biosciences plans a clincial trial for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top